Clinical Trials Directory

Trials / Completed

CompletedNCT07125911

Effect of Common Analgesia on Pulp Sensibility

COMPARISON OF THE EFFECT OF COMMON ANALGESICS ON PULPAL SENSIBILITY TESTS: A CLINICAL TRIAL

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
122 (actual)
Sponsor
HITEC-Institute of Medical Sciences · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

his study will investigate whether commonly used analgesics - 400 mg ibuprofen and 500 mg paracetamol - influence the accuracy of pulpal sensibility tests (cold test and electric pulp test) in patients with symptomatic irreversible pulpitis. Analgesics are often taken prior to dental visits and may mask endodontic symptoms, affecting diagnosis. Participants will be randomly assigned to receive either ibuprofen or paracetamol in a double-blind design. Test responses and pain levels will be measured before and 30 minutes after medication to assess any masking effect.

Conditions

Interventions

TypeNameDescription
DRUGIbuprofen 400 mg (if necessary)Single oral dose of 400 mg ibuprofen administered in a blinded capsule. Prior to dosing, baseline pulpal sensibility tests (cold test with Endo-Ice and Electric Pulp Test) and pain rating (VAS) will be recorded on a contralateral healthy tooth and the target tooth with symptomatic irreversible pulpitis. The drug is given orally and tests are repeated 30 minutes after ingestion. Participants are monitored for adverse effects. Participants who cannot take NSAIDs are excluded
DRUGParacetamol 500 mgA single oral dose of 500 mg paracetamol administered in a blinded capsule. Baseline pulpal sensibility testing (cold test with Endo-Ice and Electric Pulp Test) and pain level assessment using a Visual Analogue Scale (VAS) will be performed on both the tooth with symptomatic irreversible pulpitis and a contralateral healthy tooth prior to administration. The same tests will be repeated 30 minutes after ingestion to evaluate any masking effect on test results.

Timeline

Start date
2024-04-07
Primary completion
2025-04-07
Completion
2025-04-07
First posted
2025-08-15
Last updated
2025-08-15

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07125911. Inclusion in this directory is not an endorsement.